Sildenafil sublingual - iX Biopharma

Drug Profile

Sildenafil sublingual - iX Biopharma

Alternative Names: PheoniX™; Sildenafil citrate - iX Biopharma; Sildenafil wafer - iX Biopharma; WAFESIL

Latest Information Update: 02 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator iX Biopharma
  • Class Erectile dysfunction therapies; Phenyl ethers; Piperazines; Purines; Small molecules; Sulfones
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Erectile dysfunction

Most Recent Events

  • 19 Jun 2018 Registered for Erectile dysfunction in Australia (Sublingual)
  • 08 Feb 2018 iX Biopharma has patent protection for WaferiX drug delivery technology in China, Canada, South Africa, Germany, France, United Kingdom, Italy, Spain, Netherlands, Turkey, Switzerland, Sweden, Poland, Belgium, Austria, Norway, Denmark, Ireland and Finland
  • 08 Feb 2017 iX Biopharma announces intention to submit an application for registration to the Therapeutics Goods Administration, Australia for Erectile dysfunction
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top